Résultats
Résultats trimestriels et annuels des sociétés cotées en Suisse et en Europe, et la réaction du marché.
Lindt & Sprüngli slashes 2026 revenue growth outlook after European slump
Swiss chocolate maker cuts full-year organic revenue growth forecast to 0-2% from 4-6%, citing consumer price sensitivity and extreme summer heat in Europe.
Lindt & Sprüngli Cuts 2026 Sales Growth Forecast, Shares Drop
Swiss chocolate maker trims organic revenue growth outlook to 0–2% from 4–6%, citing European heat and consumer price sensitivity.
Verbio Reports Stronger Q4 Results; Biofuels Producer Skids in Premarket Trade
German biofuels maker Verbio posted fourth-quarter EBITDA of EUR 88.2 million, snapping a year-ago loss, but shares fell 0.8% premarket after full-year guidance missed investor expectations.
Peach Property Group Cuts Debt in Half, Beats Leverage Target on Track Early
The German-Swiss landlord reported a 25% rise in H1 adjusted EBITDA to EUR 30 million and cut total debt roughly in half, reaching its 2028 loan-to-value target two years ahead of schedule.
Peach Property cuts debt, halves vacancy rate in H1 2026 turnaround
Swiss-listed German landlord reports EUR 29.9m adjusted EBITDA, up 25%, as strategic portfolio shrinks to 80% of assets and LTV falls to 45.2%.
KWS SAAT Reports Resilient Margins as Sales Decline in FY 2025/26
German seedmaker posts €1.63 billion in sales, down 3%, but net income climbs 13% on FX gains and AgReliant deconsolidation. Shares fall 7.6%.
UBS Shares Fall as Capital Rules Weigh on Margins and Q2 Earnings Miss
UBS Group reported Q2 EPS of $0.87, below consensus, as proposed Swiss capital requirements threaten to cut earnings by up to 10%.
Helvetia Baloise reports strong H1 results, raises synergy target
Swiss insurer posts underlying earnings of CHF 631.6m in first half, raising full-year synergy capture guidance to around 60% amid merger integration progress.
Helvetia Baloise posts 25.7% earnings rise in H1 2026, RoaE reaches 18.7%
The Swiss insurer reported CHF 632 million underlying earnings, a 25.7% jump year‑on‑year, and an annualised return on adjusted equity of 18.7%, beating its 16‑18% target.
AEVIS Victoria H1 2026 profit gains lift shares 4.4% to $14.3
AEVIS Victoria reported a 6.9% rise in NAV to CHF 26.75 per share and a 43% drop in interest expense, sending its stock 4.38% higher to a new 52‑week high of $14.30.
Inter Cars Reports Strong H1 2026 Growth, Stock Dips 0.3%
Polish auto-parts distributor posts 19% international revenue growth and improves leverage; expansion in Germany and automation projects underpin long-term outlook.
Helvetia Baloise H1 Profit Drops on Merger Charges, Underlying Earnings Jump
Swiss insurer reports IFRS net income of 84.6M CHF, down sharply from 320.1M, hit by accelerated amortisation of 671.7M in merger intangibles; underlying earnings more than double to 631.6M.
Aevis Victoria lifts H1 2026 profit 30%, revenue edges up
The Swiss holding group posted a 30% rise in net profit to CHF 5.4 million, driven by stronger healthcare and hospitality margins.
Helvetia Baloise posts CHF 632M underlying H1 earnings, IFRS profit hit by merger write-down
Underlying earnings rose to CHF 631.6 million in the first half of 2026, while IFRS profit fell to CHF 84.6 million after a CHF 671.7 million accelerated write-down on intangible assets from the Baloise merger.
Helvetia Baloise posts strong H1 results with synergies ahead of schedule
Insurance giant reports CHF 631.6m underlying earnings for H1 2026, raising synergy outlook to around 60% of its CHF 650m long-term target.
Bioversys Posts Wider H1 Loss, Remains Funded Through 2028
Basel biotech reports CHF 15.6 mln net loss in first half, cites first Shionogi partnership revenue; cash runway extends to late 2028.
Partners Group reports H1 results; Layton steps down as CEO
Management income rises 6% to CHF 905m as AuM reaches USD 186bn; Co-CEOs Cagnati and Jenkner appointed effective January 2027.
Feintool posts H1 2026 profit rebound, shares rise 4%
Feintool International Holding AG reported a 5.6% rise in H1 sales, swung to a CHF 8.8 million EBIT and posted its first positive net result since 2023, sending the stock up about 4%.
Organon shares under pressure as Q2 earnings loom after Q1 miss
Drugmaker faces investor scrutiny as analysts project sequential earnings rebound despite YoY declines. Sun Pharma’s $11.75 billion bid looms over the company’s near-term outlook.
Key earnings to watch next week beyond Nvidia
PDD, Intuit, Salesforce and CrowdStrike report alongside Marvell Technology and consumer-health names. Earnings reflect AI demand, Chinese spending and beaten-down software valuations.
BizLink posts Q2 2026 revenue, EPS beat on margin recovery
Taiwanese connector maker BizLink International reported a 37% YoY revenue jump and record EPS, citing robust AI-driven demand and sequential margin expansion. Shares rose 1.1% on the news.
Catella Q2 2026 revenue drops 47% as disposal income fades, shares fall 3.7%
Swedish financial services group Catella reported a 47% year-on-year decline in Q2 2026 revenue to SEK 400 million, with underlying net revenue rising 5% to SEK 310 million. Shares slipped 3.7% after the earnings call.
Mayr-Melnhof raises profit target to over €330 mln by 2027
Austrian packaging group lifts full-year guidance after strong H1 2026 earnings and Fit-For-Future program delivery. Shares trade near €80.80.
Sonic Healthcare FY 2026 earnings miss forecasts, shares slide 9.9%
The Australian pathology group posted 13% revenue growth but EPS fell short of expectations, prompting a near‑10% drop in its stock and a modest dividend increase.